Products
Ixabepilone is commercially available as an infusion preparation (Ixempra). It has been approved in many countries since 2009.
Effects
Ixabepilone (ATC L01DC04) has cytostatic and antitumor properties.
Indications
Breast cancer
Ixabepilone is commercially available as an infusion preparation (Ixempra). It has been approved in many countries since 2009.
Ixabepilone (ATC L01DC04) has cytostatic and antitumor properties.
Breast cancer
